Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

China flag China · Delayed Price · Currency is CNY
22.44
+0.22 (0.99%)
Apr 28, 2026, 3:04 PM CST
-0.49%
Market Cap 22.79B
Revenue (ttm) 6.01B
Net Income (ttm) 1.07B
Shares Out 1.02B
EPS (ttm) 1.06
PE Ratio 21.15
Forward PE 17.67
Dividend 0.40 (1.80%)
Ex-Dividend Date May 14, 2025
Volume 12,317,980
Average Volume 10,649,892
Open 21.52
Previous Close 22.22
Day's Range 21.52 - 22.62
52-Week Range 20.74 - 29.30
Beta -0.17
RSI 52.10
Earnings Date Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, ... [Read more]

Sector Healthcare
Founded 1978
Employees 6,003
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002262
Full Company Profile

Financial Performance

In 2025, SHE:002262's revenue was 5.91 billion, an increase of 3.75% compared to the previous year's 5.70 billion. Earnings were 1.06 billion, a decrease of -7.54%.

Financial Statements

News

Luye Pharma Grants Nhwa Rights To Commercialize Three LAI Antipsychotics In Chinese Mainland

(RTTNews) - The board of Luye Pharma Group Ltd. (2186.HK) announced that certain subsidiaries of the Group have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., a subsid...

4 months ago - Nasdaq